Fairtree Asset Management Pty Ltd Makes New Investment in Edwards Lifesciences Corporation $EW

Key Points

• Fairtree Asset Management initiated a position in Edwards Lifesciences by purchasing 26,339 shares valued at approximately $2.38 million, representing 0.9% of its portfolio. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences reported quarterly earnings of $0.78 per share, exceeding estimates of $0.74, while revenue rose 13.6% year over year to $1.74 billion. The company issued third-quarter 2026 EPS guidance of $0.71–$0.77 and full-year guidance of $2.95–$3.05.
• Shares were trading at $90.02 after declining 2.4%. Analysts remain broadly positive, with a “Moderate Buy” consensus rating and an average price target of $100.27, although insiders sold 25,570 shares worth about $2.22 million over the past 90 days.

Fairtree Asset Management Pty Ltd purchased a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 26,339 shares of the medical research company's stock, valued at approximately $2,383,000. Edwards Lifesciences comprises 0.9% of Fairtree Asset Management Pty Ltd's investment portfolio, making the stock its 26th biggest position.

A number of other hedge funds and other institutional investors have also recently modified their holdings of EW. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences during the first quarter valued at $25,000. JPL Wealth Management LLC purchased a new position in Edwards Lifesciences in the 3rd quarter worth about $25,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences during the 4th quarter valued at about $26,000. RMG Wealth Management LLC bought a new position in Edwards Lifesciences during the 1st quarter valued at about $26,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $27,000. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president directly owned 40,034 shares of the company's stock, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 25,570 shares of company stock valued at $2,219,390. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Trading Down 2.4%

Edwards Lifesciences stock opened at $90.02 on Friday. The business has a 50-day simple moving average of $89.12 and a two-hundred day simple moving average of $84.63. The company has a market cap of $51.83 billion, a P/E ratio of 51.74, a P/E/G ratio of 2.32 and a beta of 0.85. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the prior year, the firm earned $0.67 EPS. The business's revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on EW. Piper Sandler reiterated an "overweight" rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Mizuho increased their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. UBS Group assumed coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They issued a "buy" rating and a $110.00 target price on the stock. Leerink Partners raised shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source